Development of solid lipid nanoparticles containing ionically complexed chemotherapeutic drugs and chemosensitizers

Strategies for optimizing polymer-lipid hybrid nanoparticle-mediated drug delivery

“…[1,3] Since then, various PLN formulations have been developed to encapsulate a single anticancer drug, [4] or co-encapsulate a drug with a chemosensitizer, [1,3] a drug with a P-glycoprotein (P-gp) inhibitor, [5] or dual anticancer drugs of synergy. [6] PLN formulations have also been developed to deliver biologics for gene therapy and immunotherapy, including siRNA [7] or siRNA with an anticancer drug.…”

“…endogenous fatty acids). Up to date, reported PLN formulations can be divided into two major categories as schematically illustrated in Figure 1: type A -monolithic matrix PLN, where polymer and drug(s) are homogeneously distributed in the solid lipid matrix, [1,[3][4][5][6][9][10][11][12] and type Bcore-shell PLN, where drug-containing polymer core is covered by a single layer of phospholipid. [7,8,13] The latter is sometimes called lipid-polymer hybrid nanoparticles (LPN) in literature.…”

Effect of Anionic Polymers on Drug Loading and Release from Clindamycin Phosphate Solid Lipid Nanoparticles

“…Afterward, the mixture was further treated by sonication (90 W) for 15 min at 75 °C. The emulsion was poured into cold water (2 -4 °C) to a final volume of 25 ml [10], and then the suspension was passed through a homogenizer (Emulsiflex-c3, Avestin, Canada) for five cycles (30 s for each cycle) at 20,000 bars. Particle size determination…”

“…SLNs are usually applicable for entrapping lipophilic drugs [9,10]. However, for loading highly water-soluble, ionic drugs such as clindamycin, SLN formulations face the challenge of low drug partitioning in the lipid phase [11].…”

Solid Lipid Nanoparticles as Drug Delivery System for Water-Insoluble Drugs

“…However, these studies also showed that SLNs delivered reduced amount of drugs into Serpe, 2006;Ying, 2008;Wong, 2004Wong, , 2006aWong, , 2006bCavalli, 1993 Han, 2008ibuprofen Casadei, 2006Paolicelli, 2008idarubicin Cavalli, 1993insulin Battaglia, 2007Bi, 2009;Gallarate, 2008;Liu 2008,a,d,;Sarmento, 2007magnetite Hsu, 2008methotrexate Paliwal, 2008Ruckmani, 2006mitoxanthrone Lu, 2006nimesulide Bondi, 2009nitrendipine Bhaskar, 2009bKumar, 2007;Manjunath, 2006olanzapine Vivek, 2007oridonin Zhang, 2005oxymatrine Sun, 2007paclitaxel Dong, 2008Lee, 2007;Cavali, 2000;Stevens, 2004;Serpe, 2004;Chen, 2001 (2010) heart, lung, spleen, liver and kidney (Zara et al, 2000;Fundaro et al, 2000;, which suggest that biodistribution of drugs in SLNs can vary depending on the composition of SLNs.…”